Folia Neuropathologica

Abstract

3/2022 vol. 60
Original paper

MiR-137 targets and regulates E2F7 to suppress progression of glioma cells

  1. The Fourth Department of Neurosurgery, Tangshan Gongren Hospital, Tangshan, Hebei, P.R. China
  2. The Fourth Department of Neurology, Tangshan Gongren Hospital, Tangshan, Hebei, P.R. China
  3. Department of Traditional Chinese Medicine, Tangshan Gongren Hospital, Tangshan, Hebei, P.R. China
  4. Hangzhou, China
Folia Neuropathol 2022; 60 (3): 346-354
Online publish date: 2022/09/29
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease

Introduction

The paper aimed to explore the mechanism of miR-137 in modulating glioma.

Material and methods

qRT-PCR detected miR-137 and E2F7 mRNA expression in cells. The protein expression of E2F7 was measured using Western blot assay. Cell proliferation, scratch healing, transwell and programmed cell death assays were conducted to examine the influences of the genes on the biological function of glioma cells. The dual-luciferase assay verified the interaction between miR-137 and E2F7.

Results

MiR-137 was lowly expressed in glioma cells, and E2F7 was highly expressed. MiR-137 suppressed progression and promoted programmed cell death of glioma cells. MiR-137 could target and negatively regulate E2F7 expression to further accelerate programmed cell death of glioma cells.

Conclusions

It was found that miR-137 could target E2F7 to restrain cell progression and accelerate programmed cell death of glioma cells, which is helpful to search for new molecular therapeutic targets for glioma.

Share
without publication fees